A549, A549 (KRAS) cells, ALK, BIM, ECLC5-GLx, EGFR, EGFRex19del, EGFRex19del/MDM2amp, ERK, KRAS, L13BS1, LUAD, LUAD12c, LUADs, LX-285, Lung Adenocarcinoma, MAPK, MDM2, MDM2amp, MEK, MET, METex14, METex14/, PUMA, Patient, Patient-, RET, SW1573, TP53, TRIM33, TRIM33-RET/MDM2amp, capmatinib, cell lines, lung adenocarcinomas, milademetan, oncogenic driver mutations, p53, patient, patient-derived LUAD models, patients, selpercatinib, trametinib, tumor, tumors